145 related articles for article (PubMed ID: 7623960)
21. Antagonism by naloxone of morphine-induced single-dose dependence and antinociception in mice.
Smits SE
Res Commun Chem Pathol Pharmacol; 1976 Dec; 15(4):689-96. PubMed ID: 12548
[TBL] [Abstract][Full Text] [Related]
22. Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine.
Vela G; Ruiz-Gayo M; Fuentes JA
Neuropharmacology; 1995 Jun; 34(6):665-8. PubMed ID: 7566503
[TBL] [Abstract][Full Text] [Related]
23. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity.
Martin JR; Takemori AE
J Pharmacol Exp Ther; 1987 Apr; 241(1):48-55. PubMed ID: 3572795
[TBL] [Abstract][Full Text] [Related]
24. Acutely administered clozapine does not modify naloxone-induced withdrawal jumping in morphine-dependent mice.
Ballard TM; McAllister KH
Pharmacol Biochem Behav; 1999 Feb; 62(2):285-90. PubMed ID: 9972695
[TBL] [Abstract][Full Text] [Related]
25. Substance P-(1-7), a substance P metabolite, inhibits withdrawal jumping in morphine-dependent mice.
Kreeger JS; Larson AA
Eur J Pharmacol; 1993 Jul; 238(1):111-5. PubMed ID: 7691618
[TBL] [Abstract][Full Text] [Related]
26. Hyperglycemic suppression of morphine withdrawal signs in the rat.
Akunne HC; Soliman KF
Psychopharmacology (Berl); 1988; 96(1):1-6. PubMed ID: 3147467
[TBL] [Abstract][Full Text] [Related]
27. Effects of chronic administration of calcium-magnesium soft gels on morphine tolerance and dependence in mice.
Khajehali E; Sadeghi HM; Rabbani M
Magnes Res; 2009 Jun; 22(2):81-8. PubMed ID: 19658277
[TBL] [Abstract][Full Text] [Related]
28. Prevention of precipitated withdrawal symptoms by activating central cholinergic systems during a dependence-producing schedule of morphine in rats.
Buccafusco JJ; Zhang LC; Shuster LC; Jonnala RR; Gattu M
Brain Res; 2000 Jan; 852(1):76-83. PubMed ID: 10661498
[TBL] [Abstract][Full Text] [Related]
29. Protective effects of atorvastatin against morphine-induced tolerance and dependence in mice.
Pajohanfar NS; Mohebbi E; Rad A; Pejhan A; Nazemi S; Amin B
Brain Res; 2017 Feb; 1657():333-339. PubMed ID: 28062186
[TBL] [Abstract][Full Text] [Related]
30. Effects of harman and harmine on naloxone-precipitated withdrawal syndrome in morphine-dependent rats.
Aricioglu-Kartal F; Kayir H; Tayfun Uzbay I
Life Sci; 2003 Sep; 73(18):2363-71. PubMed ID: 12941438
[TBL] [Abstract][Full Text] [Related]
31. The physical dependence liabilities of oxybutynin and morphine in rats.
Algate DR; Beard DJ
Arzneimittelforschung; 1985; 35(10):1577-9. PubMed ID: 4074417
[TBL] [Abstract][Full Text] [Related]
32. Effects of ethylenediamine on morphine analgesia and tolerance-dependence in mice.
Contreras E; Tamayo L
Gen Pharmacol; 1985; 16(5):529-31. PubMed ID: 4054578
[TBL] [Abstract][Full Text] [Related]
33. beta-Lactam antibiotic inhibits development of morphine physical dependence in rats.
Rawls SM; Baron DA; Kim J
Behav Pharmacol; 2010 Mar; 21(2):161-4. PubMed ID: 20215965
[TBL] [Abstract][Full Text] [Related]
34. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
Cichewicz DL; Welch SP
J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
[TBL] [Abstract][Full Text] [Related]
35. [Precipitation and prevention of abstinence in acutely morphinized rats and mice: comparisons between naloxone, naltrexone, and diprenorphine (author's transl)].
Tremblay E; Colombel MC; Jacob J
Psychopharmacology (Berl); 1976 Aug; 49(1):41-8. PubMed ID: 822446
[TBL] [Abstract][Full Text] [Related]
36. Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice.
Dambisya YM; Lee TL
Br J Pharmacol; 1996 Mar; 117(5):914-8. PubMed ID: 8851510
[TBL] [Abstract][Full Text] [Related]
37. Suppression of naloxone-precipitated withdrawal jumps in morphine-dependent mice by stimulation of prostaglandin EP3 receptor.
Nakagawa T; Minami M; Katsumata S; Ienaga Y; Satoh M
Br J Pharmacol; 1995 Nov; 116(6):2661-6. PubMed ID: 8590986
[TBL] [Abstract][Full Text] [Related]
38. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence.
Liu J; Schulteis G
Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289
[TBL] [Abstract][Full Text] [Related]
39. Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal.
Cavun S; Göktalay G; Millington WR
J Pharmacol Exp Ther; 2005 Nov; 315(2):949-58. PubMed ID: 16079299
[TBL] [Abstract][Full Text] [Related]
40. Nuclear factor-kappa-B inhibitor modulates the development of opioid dependence in a mouse model of naloxone-induced opioid withdrawal syndrome.
Rehni AK; Bhateja P; Singh TG; Singh N
Behav Pharmacol; 2008 May; 19(3):265-9. PubMed ID: 18469544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
